Skip to main content
OpenTrials
Completed

NCT Number: NCT04158752

Anti-CGRP for Inflammation and Pain Modulation in Small Fiber Neuropathy/Fibromyalgia

The investigators will treat patients (targeting enrollment of n=20) who suffer from trigeminal or glossopharyngeal nerve pain in the context of painful small fiber neuropathy. The primary pain-related objective is reduction of pain and reduced use of rescue and other anti-pain medications. Another goal is to monitor and confirm the safety profile established in the migraine population, during previous Phase 3 trials.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Duke University

Durham, North Carolina, 27705, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18-80 years old.
  • The patient must have an assigned diagnosis of non-neuralgic trigeminal nerve pain G50.1, with all its permutations listed in the ICD10 explicitly allowed. Co-morbid trigeminal neuralgia G50.0 and G43. … related headache codes are allowed. As an alternative to trigeminal nerve pain G50.1, glossopharyngeal nerve pain will be another inclusion criterion, with a G52.1 diagnosis and explicit mentioning of pain mediated by or in the innervation territory of the glossopharyngeal nerve.

In addition, patients have to be diagnosed with a painful small fiber neuropathy. This diagnosis is based on a skin biopsy or biopsy of an innervated surface epithelium with nerve fiber density count. The required ICD10 diagnostic codes are G63.3, G60.8, G62.8. Co-morbidity with a fibromyalgia-related disorder will be allowed, typically summarized under a diagnosis code of M79.7.

Exclusion criteria

  • Patients that have a history of allergy or allergy-like incompatibility with a biologic that contains a human or humanized monoclonal antibody will be excluded.
  • Female patients of child-bearing age who are or want to become pregnant will be excluded. In case such a patient intends to participate, then she has to commit to a pregnancy prevention regimen that is based on hormonal contraceptive or intra-uterine device.

Treatment and study plan

Galcanezumab

Drug

Injection of study drug at 3 timepoints (day 30, day 60, day 90)

Primary outcomes

  1. Change in Pain Score

    Time frame: Baseline (day 0), 45, 60, 75, 90, 105, 135, and 180 days

    Patient reported 0-10 analog pain scale, where 0 = no pain and 10 = worst pain imaginable. Reported as the change between timepoints.

  2. Number of Participants With a Change in Use of Anti-pain Medication

    Time frame: Baseline through Day 135

    Patient reported; any use of anti-pain medication.

  3. Total Number of Adverse Events by Severity

    Time frame: Collected through Day 180

    Recording all potential adverse events, based on lab results, patient side effects logs, patient vital sign measurement, and medical record review. Adverse events can be classified into five severity grades (1 = mild, 2 = moderate, 3 = severe, 4 = life threatening, and 5 = death).

Secondary outcomes

  1. Change in Level of TNF-alpha as a Marker of Pain or Inflammation

    Time frame: Baseline, Day 180

    Blood testing for presence of cytokine/chemokine pain or inflammation markers in patients' serum

  2. Change in Level of IL-6 as a Marker of Pain or Inflammation

    Time frame: Baseline, Day 180

    Blood testing for presence of cytokine/chemokine pain or inflammation markers in patients' serum

Other outcomes

  1. Change in Circadian Rhythm Impairment

    Time frame: Daily, from Baseline through Day 180

    Based on data from Wearable Sleep Monitor

  2. Presence or Absence of DNA Polymorphisms That Predispose Treated Patients to Accentuated Responses of Either Lack of Response or Particularly Potent Response

    Time frame: Day 0

    Genomic DNA testing

Sponsors and collaborators

Lead sponsor

Duke University

Other

Collaborators

  • Eli Lilly and Company

Registry information

Official study title

Anti-CGRP Neutralizing Antibody for Modulation of Neurogenic Inflammation in Trigeminal and Glossopharyngeal Pain Associated With Small Fiber Neuropathy/Fibromyalgia

Important dates

Study start
2020
Primary completion
2023
Study completion
2023
First posted
Nov 12, 2019
Registry last updated
Feb 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.